Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search span> per sponsor: Pfizer Inc 235 East 42nd Street, New York, NY10017
Woman and Man Max 99 years
Pfizer Inc 235 East 42nd Street, New York, NY10017
Update Il y a 5 ans
RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXITINIB (AG-013736) WITH OR WITHOUT DOSE TITRATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
To compare the objective response rate (ORR) in patients receiving axitinib with or without dose titration (Arms A and B)
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc 235 East 42nd Street, New York, NY10017 US
Update Il y a 5 ans
A clinical trial to determine if the investigational MnB vaccine works when 2 or 3 doses of the vaccine is given to adolescents
Co-Primary Objectives: To assess the immune response as measured by serum bactericidal assay performed with MnB strains expressing LP2086 subfamily A and B proteins, measured 1 month after the thi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc 235 East 42nd Street, New York, NY10017
Update Il y a 5 ans
A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAILURE OF ONE PRIOR ANTIANGIOGENIC THERAPY
Primary Objective: To compare the OS of patients with advanced HCC receiving axtitinib + best supportive care (BSC) versus (vs) placebo + BSC following failure of one prior antiangiogenic therapy.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc 235 East 42nd Street, New York, NY10017
Update Il y a 5 ans
A 16 WEEK OPEN-LABEL OUTPATIENT, RANDOMIZED, PARALLEL STUDY ASSESSING THE IMPACT OF TWO DIFFERENT INITIAL DOSE PRESCRIPTIONS FOR DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE POORLY CONTROLLED ON A COMBINATION OF TWO OR MORE ORAL AGENTS
The primary objective of this study is to assess whether a simple initial dose prescription of inhaled insulin (Exubera) achieves glycemic control (HbA1c) after 16 weeks that is noninferior compared t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc 235 East 42nd Street, New York, NY10017
Update Il y a 5 ans
A 17-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER TRIAL OF PREGABALIN FOR THE TREATMENT OF CHRONIC CENTRAL NEUROPATHIC PAIN AFTER SPINAL CORD INJURY
To evaluate the efficacy of pregabalin compared with placebo for the treatment of chronic central neuropathic pain after spinal cord injury.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc 235 East 42nd Street, New York, NY10017
Update Il y a 5 ans
A PHASE 2 RANDOMIZED, MULTICENTER, ACTIVE COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF COADMINISTRATION OF CP-690,550 AND MYCOPHENOLATE MOFETIL / MYCOPHENOLATE SODIUM IN DE NOVO KIDNEY ALLOGRAFT RECIPIENTS
1) To compare the incidence of clinical biopsy-proven acute rejection (BPAR) (as interpreted by the central blinded pathologist) of combination regimens of CP-90,550 and mycophenolate mofetil (MMF) / ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc 235 East 42nd Street, New York, NY10017
Update Il y a 5 ans
A study in patients with Non-Hodgkin Lymphoma (NHL) to evaluate safety and effectiveness of a new drug combination compared to 2 other drug combinations that have already been studied in clinical trials. This study will include patients who have already received therapy for their NHL (but it returned or was not completely cured), and now intense chemotherapy is not the best treatment option due to reasons like health or age. The types of NHL include Diffuse Large B-Cell Lymphoma and others
To evaluate efficacy as measured by overall survival (OS), with a goal of demonstrating the superiority of inotuzumab ozogamicin when administered in combination with rituximab, compared with an act...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc 235 East 42nd Street, New York, NY10017
Update Il y a 5 ans
AG-013736 (axitinib) for the treatment of metastatic renal cell cancer (mRCC)
Compare the progression-free survival (PFS) of treatment-naïve patients with mRCC receiving AG-013736 vs sorafenib. Estimate the progression-free survival (PFS) of previously-treated Asian patien...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc 235 East 42nd Street, New York, NY10017
Update Il y a 5 ans
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF cp 690,550
To estimate the incidences of LPD, lymphoma and important infections over 2 years in subjects with RA who completed or discontinued a qualifying CP 690,550 clinical trial (randomized clinical trial wi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc 235 East 42nd Street, New York, NY10017
Update Il y a 5 ans
A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE TREATMENT OF SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO METHOTREXATE ALONE
The primary objective is to compare the efficacy of 6 dose levels of oral CP 690,550 (20 mg once daily [QD] and 15 mg, 10 mg, 5 mg, 3 mg and 1 mg twice daily [BID]), versus placebo, for the treatment ...
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
Next